Literature DB >> 18220568

Comparison of kinetic parameters for drug oxidation rates and substrate inhibition potential mediated by cytochrome P450 3A4 and 3A5.

Toshiro Niwa1, Norie Murayama, Chie Emoto, Hiroshi Yamazaki.   

Abstract

Cytochrome P450 (P450 or CYP) 3A is one of the most important P450 subfamilies in terms of its broad substrate specificity and relatively high abundance in humans. The substrate specificities of CYP3A4 and CYP3A5 are generally overlapped, but sometimes could differ from each other. It is still important to understand drug interactions more precisely in individual subjects. However, there are few review articles regarding comparative drug oxidation rates catalyzed by CYP3A4 and CYP3A5 and/or substrate inhibition potential towards CYP3A4 and CYP3A5. In this article, we summarize 1) Michaelis-Menten constants (Km), maximal velocities (Vmax), and intrinsic clearance (Vmax/Km) values for 63 substrates (94 reactions) mediated by CYP3A4 and/or CYP3A5, 2) inhibition constants (Ki) and 50% inhibitory concentrations (IC50) of 18 substrates, and 3) maximum inactivation rate constants (kinact) of 14 inhibitors from the literature. The relative contribution of polymorphic CYP3A5 compared with inducible CYP3A4 varies with the substrates and the reaction positions of the substrates. Inhibitory effects of azole antifungal agents and macrolide antibiotics, with low Ki and/or IC50 values for CYP3A4, are likely to be determinant factors for predominant drug interactions in humans, although Asian subjects with relatively high frequency of genetic CYP3A5 expressers should be carefully treated with CYP3A substrates. The collective findings in our present survey provide fundamental and useful information for drug oxidations catalyzed by CYP3A4 and CYP3A5, in spite of some contradictive kinetic parameters for the same reactions reported from many laboratories in different conditions. To understand causal factor(s) and mechanism(s) for such different reports summarized here is still one of the hot research topics to be solved in current drug metabolism.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18220568     DOI: 10.2174/138920008783331121

Source DB:  PubMed          Journal:  Curr Drug Metab        ISSN: 1389-2002            Impact factor:   3.731


  19 in total

1.  Human liver microsomal cytochrome P450 3A enzymes involved in thalidomide 5-hydroxylation and formation of a glutathione conjugate.

Authors:  Goutam Chowdhury; Norie Murayama; Yusuke Okada; Yasuhiro Uno; Makiko Shimizu; Norio Shibata; F Peter Guengerich; Hiroshi Yamazaki
Journal:  Chem Res Toxicol       Date:  2010-06-21       Impact factor: 3.739

2.  Effect of cytochrome P450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin.

Authors:  Jaekyu Shin; Daniel F Pauly; Michael A Pacanowski; Taimour Langaee; Reginald F Frye; Julie A Johnson
Journal:  Pharmacotherapy       Date:  2011-10       Impact factor: 4.705

3.  To Apply Microdosing or Not? Recommendations to Single Out Compounds with Non-Linear Pharmacokinetics.

Authors:  Sieto Bosgra; Maria L H Vlaming; Wouter H J Vaes
Journal:  Clin Pharmacokinet       Date:  2016-01       Impact factor: 6.447

Review 4.  The role of ADME pharmacogenomics in early clinical trials: perspective of the Industry Pharmacogenomics Working Group (I-PWG).

Authors:  Larry Tremaine; William Brian; Terrye DelMonte; Stephan Francke; Peter Groenen; Keith Johnson; Lei Li; Kimberly Pearson; Jean-Claude Marshall
Journal:  Pharmacogenomics       Date:  2015-11-30       Impact factor: 2.533

5.  Cytochrome P450 3A Enzymes Catalyze the O6-Demethylation of Thebaine, a Key Step in Endogenous Mammalian Morphine Biosynthesis.

Authors:  Valerie M Kramlinger; Mónica Alvarado Rojas; Tatsuyuki Kanamori; F Peter Guengerich
Journal:  J Biol Chem       Date:  2015-07-08       Impact factor: 5.157

6.  Quantitative Prediction of CYP3A4- and CYP3A5-Mediated Drug Interactions.

Authors:  Yingying Guo; Aroonrut Lucksiri; Gemma L Dickinson; Raj K Vuppalanchi; Janna K Hilligoss; Stephen D Hall
Journal:  Clin Pharmacol Ther       Date:  2019-09-12       Impact factor: 6.875

7.  Active-site differences between substrate-free and ritonavir-bound cytochrome P450 (CYP) 3A5 reveal plasticity differences between CYP3A5 and CYP3A4.

Authors:  Mei-Hui Hsu; Eric F Johnson
Journal:  J Biol Chem       Date:  2019-03-29       Impact factor: 5.157

8.  Characterization of T-5 N-oxide formation as the first highly selective measure of CYP3A5 activity.

Authors:  Xiaohai Li; Valer Jeso; Scott Heyward; Gregory S Walker; Raman Sharma; Glenn C Micalizio; Michael D Cameron
Journal:  Drug Metab Dispos       Date:  2013-12-11       Impact factor: 3.922

9.  Effect of CYP3A5*3 genetic variant on the metabolism of direct-acting antivirals in vitro: a different effect on asunaprevir versus daclatasvir and beclabuvir.

Authors:  Jun Matsumoto; Su Nwe San; Masachika Fujiyoshi; Ayano Kawauchi; Natsumi Chiba; Ran Tagai; Ryoko Sanbe; Shiho Yanaka; Hiroaki Sakaue; Yoshinori Kato; Hiroyoshi Nakamura; Harumi Yamada; Noritaka Ariyoshi
Journal:  J Hum Genet       Date:  2019-10-23       Impact factor: 3.172

Review 10.  Renal transplantation in patients with HIV.

Authors:  Lynda A Frassetto; Clara Tan-Tam; Peter G Stock
Journal:  Nat Rev Nephrol       Date:  2009-10       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.